CurrentHealthPartnersPolicy N/A

Gene Therapy for Hemophilia A Attestation Form

An attestation form to be completed by prescriber and patient when gene therapy for Hemophilia A is being requested, documenting assessments, follow-up monitoring commitments, informed consent items, and contact details. It governs documentation/attestation requirements rather than clinical coverage criteria or billing.

Policy Summary

PayerHealthPartners

PolicyGene Therapy for Hemophilia A Attestation Form

Policy CodePolicy N/A

Change TypeInformational

Effective Date

Next Review Date

Key ActionProvider must provide biannual follow-up assessments for up to 5 years documenting factor VIII expression, breakthrough bleeding, product utilization, and inhibitor development.

SourceLink

POLICY UPDATE CHANGES

No material clinical/coverage changes

7Prescriber/Member attestation items

Policy summary

This is an attestation form to be completed by the prescriber and patient when gene therapy for Hemophilia A is being requested. It documents prescriber assessments, patient informed consent items, follow-up monitoring commitments, and contact details. The form is informational and governs documentation and attestation requirements rather than clinical coverage determinations or billing.

Scope summary: An attestation form to be completed by prescriber and patient for gene therapy for Hemophilia A, documenting assessments, follow-up monitoring commitments, informed consent items, and contact details.

Subject: Gene Therapy for Hemophilia A Attestation Form.

Key metadata

PayerHealthPartners

PolicyGene Therapy for Hemophilia A Attestation Form

Policy NumberN/A

StatusCURRENT

Effective Date

Next Review

Last Review

Scope summaryAn attestation form to be completed by prescriber and patient when gene therapy for Hemophilia A is being requested, documenting assessments, follow-up monitoring commitments, informed consent items, and contact details. It governs documentation/attestation requirements rather than clinical coverage criteria or billing.

Prescriber attestation and follow-up requirements

Prescriber Attestation and Follow-up Requirements

Prescriber will perform and document the following:

ALL of the following

Assess treatment efficacy including evaluation of factor VIII expression
Assess treatment efficacy including breakthrough bleeding episodes
Assess treatment efficacy including factor VIII product utilization
Assess treatment efficacy including inhibitor development
Follow-up documentation schedule
- Provide documentation not more frequently than biannually
- Provide follow-up documentation for a period not to exceed 5 years post-administration
- Follow-up documentation to include evaluation of factor VIII expression
- Follow-up documentation to include breakthrough bleeding episodes
- Follow-up documentation to include factor VIII product utilization
- Follow-up documentation to include inhibitor development while the patient is under the care of the prescriber

Documentation Required

Initial efficacy assessment

Provider must assess and document treatment efficacy prior to or at administration. Documentation should include evaluation of factor VIII expression, breakthrough bleeding episodes, factor VIII product utilization, and inhibitor development.

Evaluation of factor VIII expression
Breakthrough bleeding episodes
Factor VIII product utilization
Inhibitor development

Documentation Required

Biannual follow-up documentation

Provider must provide follow-up assessments not more frequently than biannually and not to exceed 5 years post-administration. Follow-up documentation should include evaluation of factor VIII expression, breakthrough bleeding episodes, factor VIII product utilization, and inhibitor development while the patient remains under the prescriber's care.

Cadence: not more frequently than biannually
Duration: not to exceed 5 years post-administration

Member (patient) attestation obligations

Member (Patient) Attestation

Member acknowledges and agrees to the following prior to receiving gene therapy:

ALL of the following

I understand I am being prescribed a gene therapy for the treatment of hemophilia A
I am aware that the drug cost is ~ $3,000,000 for a one-time treatment and additional costs for therapy and monitoring may apply
I have received counseling relating to alcohol abstinence and use of concomitant medications and am prepared to receive this therapy as instructed
I am highly motivated to achieve a cure and to refrain from behaviors that might lead to treatment failure
I am willing and able to attend all necessary follow-up provider and lab appointments
I will notify provider if hospitalized for any reason following treatment
I am willing to participate in any health plan-initiated outreach to ensure optimal outcomes

Documentation Required

Patient attestation collection

Provider should collect and retain the patient's attestation prior to therapy administration. The attestation confirms understanding of receiving gene therapy for hemophilia A, awareness of one-time drug cost and monitoring costs, counseling received (including alcohol abstinence and concomitant medication guidance), willingness to attend follow-up visits, to notify the provider if hospitalized after treatment, and to participate in health plan outreach.

Acknowledges gene therapy for hemophilia A
Acknowledges drug cost and potential additional monitoring costs
Received counseling on alcohol abstinence and concomitant medications
Willingness to attend follow-up provider and lab appointments
Will notify provider if hospitalized after treatment
Willing to participate in health plan outreach

Background and monitoring commitments

Form captures informed consent and post-treatment monitoring commitments for patients receiving gene therapy for Hemophilia A. It emphasizes multi-year follow-up (up to 5 years) with documentation provided not more frequently than biannually.

Prescriber must assess and document treatment efficacy including: factor VIII expression; breakthrough bleeding episodes; factor VIII product utilization; and inhibitor development. These measures must be included in follow-up patient assessments while the patient is under the care of the prescriber.

When this attestation form applies

Scope & applicability

ApplicabilityThis form is required when gene therapy for Hemophilia A is being requested and must be completed by the prescriber and patient to document informed consent and monitoring commitments.

What it governsGoverns documentation and attestation requirements (assessments, biannual follow-up up to 5 years, informed consent), not coverage decisions or billing instructions.

Follow-up requirementsProvider must provide follow-up assessments not more frequently than biannually and not to exceed 5 years post-administration, documenting factor VIII expression, breakthrough bleeding, factor VIII product utilization, and inhibitor development.

Coverage stanceinformational

Document changes

statusLatest

CURRENT — No dated revisions present. Form captures informed consent and multi-year follow-up commitments for gene therapy for Hemophilia A; provider must document initial efficacy assessments and provide biannual follow-up documentation for up to 5 years including evaluation of factor VIII expression, breakthrough bleeding episodes, factor VIII product utilization, and inhibitor development.

Policy Summary

PayerHealthPartners

PolicyGene Therapy for Hemophilia A Attestation Form

Policy CodePolicy N/A

Change TypeInformational

Effective Date

Next Review Date

Key ActionProvider must provide biannual follow-up assessments for up to 5 years documenting factor VIII expression, breakthrough bleeding, product utilization, and inhibitor development.

SourceLink

On This Page